[1] BOLTON A E, PENG B, HUBERT M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects[J]. Cancer Chemother Pharmacol, 2004, 53(2): 102-106. [2] DUTREIX C, PENG B, MEHRING G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects[J]. Cancer Chemother Pharmacol, 2004, 54(4): 290-294. [3] GOLD J S, GÖNEN M, GUTIÉRREZ A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis[J]. Lancet Oncol, 2009, 10(11): 1045-1052. [4] DEMATTEO R P, LEWIS J J, LEUNG D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival[J]. Ann Surg, 2000, 231(1): 51- 58. [5] WANG R, ZHANG H, WANG Y J, et al. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9[J]. J Ethnopharmacol, 2016, 180: 87-96. [6] QIAN J F, CHEN W J, WU J M, et al. Correction to: effects and mechanism of action of Panax notoginseng saponins on the pharmacokinetics of warfarin[J]. Eur J Drug Metab Pharmacokinet, 2022, 47(3): 343. [7] CHEN X R, DU L Y, LIU M F. Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma[J]. Ann Clin Biochem, 2022, 59(4): 253-263. [8] YIN S Y, WEI W C, JIAN F Y, et al. Therapeutic applications of herbal medicines for cancer patients[J]. Evid Based Complement Alternat Med, 2013, 2013: 302426. [9] DARWEESH R S, EL-ELIMAT T, ZAYED A, et al. The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats [J]. BMC Pharmacol Toxicol, 2020, 21(1): 77. [10] WANG X, YEUNG J H. Investigation of cytochrome P4501A2 and 3A inhibitory properties of Danshen tincture[J]. Phytomedicine, 2012, 19(3/4): 348-354. [11] YUAN Y F, ZHANG H, MA W N, et al. Influence of compound Danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry[J]. Biomed Chromatogr, 2013, 27(9): 1219- 1224. [12] PENG B, LLOYD P, SCHRAN H. Clinical pharmacokinetics of imatinib[J]. Clin Pharmacokinet, 2005, 44(9): 879-894. [13] GSCHWIND H P, PFAAR U, WALDMEIER F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers[J]. Drug Metab Dispos, 2005, 33(10): 1503-1512. [14] DEMETRI G D, VON MEHREN M, BLANKE C D, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7): 472-480. [15] XIA Y Z, CHEN S L, LUO M J, et al. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors[J]. Cancer, 2020, 126(Sup 9): 2054-2061. [16] MOSLEHI J J, DEININGER M. Tyrosine kinase inhibitorassociated cardiovascular toxicity in chronic myeloid leukemia [J]. J Clin Oncol, 2015, 33(35): 4210-4218. |